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unit AAbstract In the present investigation, a series of 4-(4-pyrrol-1-yl/2,5-dimethyl-4-pyrrol-1-yl) ben-
zoic acid hydrazide analogs, some derived oxadiazoles and azines have been synthesized in good
yields and structures of these compounds were established by IR, 1H NMR, 13C NMR, mass spec-
tral and elemental analysis. The newly synthesized title compounds were evaluated for their antimi-
crobial as well as antimycobacterial activities. Among the tested compounds, 6j and 9c displayed
promising anti-tubercular activity. Further, some compounds were also assessed for their cytotoxic
activity (IC50) against mammalian Vero cell lines and A549 (lung adenocarcinoma) cell lines using
the MTT assay method. The results revealed that these compounds exhibit anti-tubercular activity
at non-cytotoxic concentrations. The docking of inhibitors into InhA using Sybyl-X 2.0 software
revealed the vital interactions and binding conformation of the inhibitors.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is a deadly disease caused by mycobacteria
of the ‘‘tuberculosis complex’’, including primarilyMycobacte-
rium tuberculosis, but also Mycobacterium bovis and Mycobac-
terium africanum (Wolinsky, 1992; Sensi and Grass, 1996). TB
has re-emerged as one of the leading causes of death worldwide
(nearly 3 million deaths annually) in the last decade (Bloom and
Murray, 1992). There will be an estimation of 1.3 million multi/
extensively drug resistant TB (M/XDR-TB) cases that need to
be treated between 2010 and 2015 (WHO, 2010).
Synthesis and molecular modeling studies of novel pyrrole analogs as antimycobacterial agents 43Due to this increased microbial resistance, new classes of
antimicrobial agents with novel mechanisms are today’s need
to ﬁght against the multidrug-resistant infections.
One of the most effective ﬁrst-line anti-TB drugs is isonia-
zid. Many isoniazid analogs have been synthesized and tested
as antimycobacterials. In a critical review published recently,
the existence of more than 3000 compounds based on the
INH core was reported, about 66% of them being hydrazones
(Ballell et al., 2005; Janin, 2007).
M. tuberculosis contains unique signature fatty acids, the
mycolic acids, that are unusually long chain a-alkyl, b-hydroxy
fatty acids of 60–90 carbons (Takayama et al., 2005). The anti-
tubercular drugs isoniazid (isonicotinic acid hydrazide (INH))
and ethionamide have been shown to target the synthesis of
these mycolic acids, which are central constituents of the
mycobacterial cell wall. Among the enzymes involved in FAS-
II, the NADH-dependent enoyl-ACP reductase encoded by the
Mycobacterium gene InhA is a key catalyst in mycolic acid bio-
synthesis. Studies over the years have established that InhA is
the primary molecular target of INH (Banerjee et al., 1994),
the drug for the past 40 years has been, and continues to be,
the frontline agent for the treatment of tuberculosis.
Molecular modeling and pharmacokinetic studies have con-
ﬁrmed that the introduction of the 1,3,4-oxadiazole ring to the
inhibitors can change their ﬂexibility, polarity as well as meta-
bolic stability, and 1,3,4-oxadiazole scaffold can also act as
acceptors of hydrogen bond formation, which makes it possi-
ble to be used as an isosteric substituent for amide or ester
groups (Guimaraes et al., 2005; Joshi et al., 2013a,b). Several
phthalazine derivatives have been reported to possess
antitumor (Loh et al., 2005; Sung Kim et al., 2004), antihyper-
tensive (Demirayak et al., 2004; Watanabe et al., 1998), anti-
convulsant (Kornet and Shackleford, 1999; Nassar, 1997),
antidiabetic (Madhavan et al., 2001; Lenz et al., 2002), antimi-
crobial (Cardia et al., 2003), antimycobacterial (Sriram et al.,
2010), and anti-inﬂammatory activities (Napoletano et al.,
2000; Chakraborti et al., 2003). Nitrogen containing heterocy-
clic molecules constitutes the largest portion of chemical enti-
ties, which are part of many natural products, ﬁne chemicals,
and biologically active pharmaceuticals. This prompted us to
explore the biological activity of such molecules through struc-
tural modiﬁcations. In the present study, synthesis, molecular
modeling and evaluation of potential InhA inhibitors having
pyrrole as the core structure are attempted. Other chemother-
apeutically-active groups into the designed structures are intro-
duced, with a hope to impart synergism to the target
compounds (Fig. 1). Surﬂex-Docking was applied to study
the interactions between 36 pyrrole-shiffbases, -oxadiazoles, -
phthalazines/pyridazines and InhA. These developed models
can help in understanding the SAR of the pyrrole derivatives
and can also serve as a valuable guide for the design of novel
inhibitors with robust potency (Fig. 2).
2. Chemistry
Synthesis of scaffolds is depicted in Schemes 1 and 2. The key
intermediate in the present study is the 4-pyrrol-1-yl benzoic
acid hydrazide 4, which was prepared by hydrazinolysis of
the ethyl ester of 4-pyrrol-1-yl benzoate 3 with hydrazine hy-
drate. The reaction of 4 with different aldehydes in alcohol
gave Schiff bases 5a–j. Cyclization of 5a–j with acetic anhy-dride afforded 1,3,4-oxadiazole derivatives 6a–j. 4-Pyrrol-1-yl
benzoic acid hydrazide 4 on condensation with different anhy-
drides afforded phthalazine and pyridazine derivatives 7a–h.
The compounds 9a–h were synthesized by treating 4-(2,5-dim-
ethylpyrrol-1-yl) benzoic acid hydrazide 8 with different
anhydrides.
3. Biological activity
3.1. Antibacterial studies
Standard bacterial strains were procured from the American
Type Culture Collection (ATCC) and Gene Bank, Institute
of Microbial Technology, Chandigarh, India. The compounds
5a–j, 6a–j, 7a–h and 9a–h were evaluated for in vitro antimicro-
bial activities by the broth micro-dilution method (Goto et al.,
1981; Villanova, 1985) against the following standard bacterial
strains: Staphylococcus aureus (ATCC 11632), Bacillus subtilis
(ATCC 60511), Escherichia coli (ATCC 10536) and Vibrio
cholera (recultured). The MICs were determined for 5a–j,
6a–j, 7a–h and 9a–h; these results are summarized in Table 1.
3.2. Anti-tubercular studies
Anti-tubercular activities of all the compounds were assessed
against M. tuberculosis H37Rv and MDR-TB using the Micro-
plate Alamar Blue Assay (MABA) method (Franzblau et al.,
1998) with the observed MICs given in Table 2. The method
used is nontoxic, uses a thermally stable reagent and shows a
good correlation with proportional and BACTEC radiometric
methods.
4. Results and discussion
4.1. Chemistry
Synthetic strategies adopted to obtain the target compounds
are depicted in Schemes 1 and 2. FTIR, 1H NMR, 13C
NMR and mass spectral data are in agreement with the pro-
posed structures of all the synthesized compounds.
The hydrazones 5a–j obtained from the hydrazide 4 showed
carbonyl amide stretching in 1653–1636 cm1 region and N–H
bands in 3271–3192 cm1 region. 1H NMR and 13C NMR
data were also in agreement with the formation of hydrazones.
1H NMR spectrum of 5g showed two singlets at d 8.44 and at d
11.94, which were attributed to the N‚CH and NH protons,
respectively.
IR spectra of 6a–j had different characteristics as they
showed no NH stretching bands and only C‚O bands in
1668–1662 cm1 region which was attributed to the C‚O
stretching of the acetyl group. 1,3,4-oxadiazoline derivative
6g obtained from the hydrazone 5g gave a singlet at d 7.14
in the 1H NMR spectrum which was attributed to the O–
CHR–N resonance of the oxadiazoline ring and a singlet at
d 2.31 was assigned for acetyl CH3. The formation of the
oxadiazolines was further supported by the 13C NMR data
of compound 6a–j. While the N‚CH carbon of compound
5g in hydrazone structure was observed at d 148.30 in its 13C
NMR spectra; the same carbon atom (OCHR–N) 6g was
observed at d 83.79 after cyclization of the oxadiazoline ring.
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44 S.D. Joshi et al.In the 13C NMR spectrum of 6g, this signal was observed at d
83.79 due to the sp3 hybridization. Further evidence for the
formation of oxadiazoline 6g was obtained by recording the
mass spectra. The mass spectrum of compound 6g showed a
molecular ion peak at m/z 347.55, which is in conformity with
the molecular formula, C20H17N3O3.Further the phthalazine/pyridazine derivatives (7a–h and
9a–h) synthesized from 4-(4-pyrrol-1-yl/2,5-dimethyl-4-pyr-
rol-1-yl) benzoic acid hydrazides (4/8) were conﬁrmed by spec-
tral analysis. FT-IR spectrum of compound 7c showed
absorption peak at 3377 cm1 for the NH group and strong
carbonyl stretching at 1792 cm1. That of 1H NMR spectra
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and multiplet in the range of d 7.67–8.08 corresponds to four
protons of phenyl and four protons of the phthalazine ring.
In the 13C NMR spectrum of 7c peaks were observed at d
168.05 and 158.44 due to two carbonyl groups in phthalazine
derivatives. The mass spectrum of compound 7c showed a
molecular ion peak at m/z 331.41, which is in conformity with
the molecular formula, C19H13N3O3.
4.2. Antibacterial and anti-tubercular activities (in vitro)
The preliminary antimicrobial screening revealed that com-
pounds 5a–j, 6a–j, 7a–h and 9a–h showed moderate to verygood inhibitory activity against all strains. The antibacterial
activities of 5a–j, 6a–j, 7a–h and 9a–h expressed in terms of
minimum inhibitory concentration (MIC) are shown in Table 1
along with the activity of ciproﬂoxacin and norﬂoxacin for
comparison. All the compounds showed enhanced activity
against Gram negative bacteria than Gram positive bacteria
with the antimicrobial activity at MIC values of 0.2 to 50 lg/
mL. Compound 9c was more active than others at the MIC va-
lue of 0.2 lg/mL against V. cholera and E. coli. All the com-
pounds showed antimicrobial activity with the MIC values
between 0.2 and 12.5 lg/mL against two Gram-negative
organisms.
The anti-tubercular screening data revealed that all the
compounds have moderate to good inhibitory activity against
both MTB and MDR-TB. In vitro antitubercular activities of
pyrrole derivatives 5a–j, 6a–j, 7a–h and 9a–h are reported in
Table 2 together with those of isoniazid (INH), rifampicin
(RFP) and ethambutol (EB) used as reference drugs. Com-
pounds 6j and 9c were quite potent inhibitors (MIC 0.2 lg/
mL) similar to isoniazid, while 5a, 5c, 6c, 6f, 6h, 7c, 9b, 9f,
9g and 9h showed good activity with inhibition of mycobacte-
rium at 0.4 lg/mL which is similar to rifampicin. The com-
pounds were also screened against MDR-TB (M.
tuberculosis) resistant to three drugs, viz., isoniazid, rifampicin
and ethambutol. Most of them showed good activity against
MDR-TB strain with MIC ranging from 0.4 to 50 lg/mL. A
good anti-TB activity may be attributed to the presence of
pharmacologically active hetero-aryl groups viz., oxadiazole,
phthalazine, pyridazine, etc., attached to the pyrrole ring. It
is encouraging to observe that compounds 6j and 9c showed
very good anti-tubercular activities against the MTB strain
(MIC 0.2 lg/mL), due to the presence of the bulky group.
Compounds 6a–j, which have the oxadiazole ring were
more active than the starting Schiff bases against some of
the test microorganisms. Phthalazine/pyridazine derivatives
containing the dimethyl group at the 2ndand 5th position on
pyrrole moiety were more active.
Table 1 Primary antibacterial activity screen results of synthesized compounds 5a–j, 6a–j, 7a–h and 9a–h pyrrole derivatives.
Compound MIC values (lg/mL)
Gram-negative organismsa Gram-positive organismsb
Vc Ec Sa Bs
5a 1.6 3.125 50 12.5
5b 12.5 3.126 50 25
5c 1.6 6.25 12.5 50
5d 1.6 0.8 25 12.5
5e 6.25 3.125 50 25
5f 6.25 6.25 50 50
5g 1.6 0.8 50 50
5h 1.6 0.8 12.5 25
5i 0.8 0.8 12.5 25
5j 1.6 0.8 12.5 12.5
6a 0.8 0.8 25 12.5
6b 0.8 1.6 12.5 50
6c 0.4 0.8 12.5 25
6d 1.6 1.6 25 50
6e 6.25 3.125 50 50
6f 6.25 6.25 12.5 50
6g 6.25 12.5 12.5 50
6h 1.6 0.8 12.5 25
6i 1.6 0.4 12.5 50
6j 0.8 0.4 6.25 25
7a 0.8 1.6 25 12.5
7b 0.8 0.4 25 50
7c 0.4 0.4 12.5 25
7d 3.125 3.125 12.5 50
7e 1.6 3.125 25 25
7f 0.4 0.4 6.25 12.5
7g 1.6 0.8 25 25
7h 1.6 1.6 50 25
9a 0.8 0.8 12.5 50
9b 0.8 0.4 50 25
9c 0.2 0.2 6.25 25
9d 0.4 0.8 50 50
9e 0.4 0.8 50 50
9f 0.4 0.4 25 50
9g 0.8 0.4 25 25
9h 0.8 0.8 12.5 50
Ciproﬂoxacin 1 2 2 2
Norﬂoxacin 1 12 2 2
In vitro antibacterial activity.
The screening organisms.
a Gram-negative bacteria: Escherichia coli ATCC 10536 (Ec), Vibrio cholera (recultured) (Vc).
b Gram-positive bacteria: Staphylococcus aureus ATCC 11632 (Sa), Bacillus subtilis ATCC 60511 (Bs).
46 S.D. Joshi et al.4.3. MTT-based cytotoxicity assay
Compounds viz., 5b, 5c, 7a, 7b, 7c, 8b, 8c, 8d, 9c and 9d with
MIC values ranging from 0.2 to 0.4 lg/mL were chosen for
cytotoxicity MTT assay against two different cell lines. The
IC50 values of these compounds are listed in Table 2. Most
of the compounds showed low toxicity and speciﬁcally the
most potent compound 9c exhibited a very good safety proﬁle
as its IC50 value was 263 lmol/L against the A549 cell line.
4.4. Molecular docking studies
All the studied inhibitors were docked into the binding site of
InhA and the energy scores of the inhibitors are also shown in
Table 3, where no precise correlations could be found betweendocking scores and MIC values. This observation is not sur-
prising, because MIC values are very complicated, not only
relating to the target inhibition, but also dealing with a number
of events. Therefore, we selected the most potent inhibitors 6j
and 9c in the experiment to perform the deeper docking study
that are discussed below.
Here, a complete overview of receptor-inhibitor binding
interactions is presented as shown in Fig. 3(A) and (B). It viv-
idly represents the interaction model of the most potent inhib-
itors 6j and 9c with InhA, respectively in which both inhibitors
are suitably situated at the InhA-binding site and there are var-
ious interactions between them and the binding region of the
enzyme.
Compound 6j showed hydrogen bonding interaction, the
hydrogen of the hydroxyl group present at the 4th position
Table 2 Cytotoxicity and antimycobacterial activity of 5a–j, 6a–j, 7a–h and 9a–h pyrrole derivatives.
Compound MIC values (lg/mL) M. tuberculosis H37Rv MDR-TB
a IC50 (lM)
b
MV cell linesc A549
d
5a 0.4 3.125 239 ± 0.2 236 ± 0.2
5b 12.5 50 NT NT
5c 0.4 0.8 230 ± 0.4 237 ± 0.3
5d 1.6 3.125 NT NT
5e 3.125 3.125 NT NT
5f 25 50 NT NT
5g 1.6 6.25 NT NT
5h 0.8 1.6 NT NT
5i 1.6 1.6 NT NT
5j 1.6 1.6 NT NT
6a 1.6 3.125 NT NT
6b 0.4 3.125 229 ± 0.2 225 ± 0.2
6c 0.4 0.4 231 ± 0.5 233 ± 0.5
6d 3.125 6.25 NT NT
6e 3.125 12.50 NT NT
6f 0.4 1.6 235 ± 0.4 241 ± 0.5
6g 1.6 3.125 NT NT
6h 0.4 3.125 238 ± 1.3 242 ± 2.1
6i 0.8 12.5 NT NT
6j 0.2 0.4 255 ± 0.2 251 ± 0.2
7a 3.125 12.5 NT NT
7b 0.4 3.125 245 ± 0.5 241 ± 0.3
7c 0.4 0.4 250 ± 0.5 252 ± 0.5
7d 1.6 3.125 NT NT
7e 0.8 3.125 NT NT
7f 0.8 0.8 NT NT
7g 1.6 0.8 NT NT
7h 1.6 0.8 NT NT
9a 1.6 3.125 NT NT
9b 0.4 1.6 252 ± 0.2 250 ± 0.5
9c 0.2 0.4 259 ± 0.3 263 ± 0.2
9d 0.8 0.8 NT NT
9e 0.8 3.125 NT NT
9f 0.4 0.4 233 ± 0.2 235 ± 0.5
9g 0.4 1.6 238 ± 0.5 247 ± 0.3
9h 0.4 0.8 244 ± 0.4 241 ± 0.3
Isoniazid 0.2 12.5 >450 >450
Rifampicin 0.4 25 >450 >450
Ethambutol 0.5 12.5 >450 >450
Cisplatin – – 1.29 9.90
Trimethoprim – – – –
Cytotoxicity and antimycobacterial activity of quinoline derivatives.
a Mycobacterial tuberculosis resistant to three drugs viz., Isoniazid (INH), Rifampicin (RFP) and Ethambutol (EB).
b Cytotoxicity is expressed as IC50, which is the concentration of compound reduced by 50% of the optical density of treated cells with respect
to untreated cells using MTT assay. Values are the means ± SEM of three independent experiments.
c Mammalian Vero cell-lines.
d A549 (lung adenocarcinoma) cell-lines.
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Gln214 carbonyl group. The substituent attached to the 2nd
position of oxadiazole was blocked by the side chains of
Pro156, Ala157, Met103 and Leu217. That of oxadiazole/
phthalazine and bridge phenyl moiety was surrounded by
Trp160, Trp222, Met161 and Leu218. Pyrrole moiety was
blocked by Trp230, Pro193, Phe97 and Met98 (Fig. 4A and
B). All compounds docked within the generated fast connolly
surface area (Fig. 5A) and that of 2,5-dimethyl pyrrole moiety
overly on ring A of PT70 and triclosan (Fig. 5B). The C-score
(Consensus score) indicated the summary of all the forces
interacted between the ligands and InhA enzyme. Crash score
revealed that inappropriate penetration into the binding sitewas in favor of compounds 5g and 6g in the series, followed
by PT70, other compounds and triclosan (Table 3). Charge
and van der Waals interactions between the protein and the li-
gand suggested that 5h, 9h, 9c, 9g and 9f were the superior li-
gands than PT70, triclosan and other compounds to bind with
ENRs. Helmholtz free energies of interactions for protein–li-
gand atom pairs prefer all the compounds over those of
PT70 and triclosan. Compounds 9h, 9g and 9f showed better
hydrogen bonding, complex (ligand–protein), and internal (li-
gand–ligand) energies than PT70, triclosan and other com-
pounds in the series. Scoring of compounds with respect to
the reward for hydrogen bonding, lipophilic contact, and
rotational entropy, along with intercept terms revealed that
Table 3 Surﬂex-Dock scores (kcal/mol) of pyrrole derivatives.
Compound C scorea Crash scoreb Polar scorec D scored PMF scoree G scoref Chem scoreg
PT70 13.60 0.96 2.13 168.341 42.822 307.070 48.411
9h 8.94 4.33 0.00 186.520 75.387 336.967 42.741
9c 8.40 3.17 0.00 176.872 76.830 303.501 42.558
9b 8.34 2.34 0.00 157.468 69.881 273.942 34.594
5j 8.34 1.23 1.99 154.427 69.277 203.209 42.959
9g 8.31 4.01 0.00 180.833 70.563 319.118 42.468
9f 8.26 4.36 0.02 189.267 72.683 329.923 44.125
5h 7.94 2.12 0.00 170.645 62.669 246.004 39.341
5i 7.72 2.12 0.00 160.533 72.757 259.661 36.396
5f 7.32 2.38 2.54 148.783 63.287 215.079 44.524
5g 7.22 0.87 2.12 131.288 69.079 192.045 39.623
5b 6.90 1.80 0.00 155.670 70.128 257.764 37.681
5a 6.84 1.45 0.84 156.277 71.116 245.316 38.241
9e 6.79 3.44 0.00 162.350 63.172 279.162 36.688
9a 6.76 3.42 0.00 158.547 61.962 272.305 34.806
9d 6.76 3.19 0.00 165.457 64.665 281.875 36.948
7c 6.71 2.54 0.00 163.266 85.542 255.498 37.087
7a 6.64 1.79 0.00 141.983 72.480 222.616 29.716
5d 6.63 2.26 0.69 167.369 68.539 265.005 40.550
7d 6.59 1.87 0.00 146.477 79.862 227.273 31.639
5c 6.45 2.48 0.00 150.114 68.507 255.631 35.557
7e 6.21 2.18 0.00 148.182 77.906 234.631 32.014
7b 6.20 1.87 0.00 142.871 71.981 222.516 29.706
7f 6.19 2.99 0.00 167.193 79.016 273.037 37.916
7g 6.19 3.01 0.00 164.483 75.566 267.392 36.739
TCL 6.18 1.99 2.55 142.307 28.832 221.306 39.726
7h 6.09 1.10 0.00 132.729 66.982 214.614 36.097
5e 5.99 2.60 0.48 168.022 67.991 282.049 41.714
6h 5.64 2.16 0.00 145.923 59.176 246.769 36.417
6j 5.62 2.92 0.94 148.507 61.542 263.692 39.000
6i 5.50 2.03 0.53 130.014 44.251 208.647 27.759
6g 5.46 0.88 0.00 126.932 75.823 201.731 33.186
6a 5.16 1.15 0.63 124.289 60.482 198.452 34.215
6b 4.86 1.35 0.00 128.593 61.808 200.417 34.926
6c 4.74 0.97 0.00 120.620 67.263 183.903 32.635
6f 4.68 1.45 0.00 131.324 59.200 198.837 33.133
6e 4.59 1.30 0.00 129.920 61.374 204.778 34.740
6d 4.06 4.14 0.00 161.239 70.668 230.881 38.250
a C Score (Consensus Score) integrates a number of popular scoring functions for ranking the afﬁnity of ligands bound to the active site of a
receptor and reports the output of total score.
b Crash score revealing the inappropriate penetration into the binding site. Crash scores close to 0 are favorable. Negative numbers indicate
penetration.
c Polar indicating the contribution of the polar interactions to the total score. The polar score may be useful for excluding docking results that
make no hydrogen bonds.
d D score for charge and van der Waals interactions between the protein and the ligand (Kuntz et al., 1982).
e PMF score indicating the Helmholtz free energies of interactions for protein–ligand atom pairs (Potential of Mean Force, PMF) (Muegge
and Martin, 1999).
f G score showing hydrogen bonding, complex (ligand–protein), and internal (ligand–ligand) energies (Jones et al., 1997).
g Chem score points for hydrogen bonding, lipophilic contact, and rotational entropy, along with an intercept term (Eldridge et al., 1997).
48 S.D. Joshi et al.compounds 5e, 5f, 9c, 9f, 9g and 9h showed increased interac-
tions with the protein than triclosan and other compounds, but
less than PT70.
4.5. Conclusions
In the present research, we have reported the synthesis of a
new series of pyrrolyl-shiffbase, -oxadiazole, -phthalazine/
pyridazine derivatives along with spectral data as well as
antibacterial and anti-tubercular activities. Their chemicalversatility, activity, and selectivity suggest that these classes
of competitive inhibitors can be considered as promising lead
compounds for further medicinal chemistry efforts for the
development of new anti-TB drugs. The in vitro studies dem-
onstrated that 6j and 9c exhibited promising anti-tubercular
activity with less toxicity. Molecular modeling and docking
studies suggested that compounds 5j, 9b, 9c, 9f, 9g and 9h
interacted with InhA enzyme more efﬁciently and hence,
these can be further developed to improve their anti-tubercu-
lar activity.
Figure 3 Compound 6j (A) and 9c (B), the MOLCAD lipophilic potential surface of the binding region was demonstrated with the color
ramp for LP ranging from brown to blue. The oxadiazole group and the thalazine group at the terminal were found in a brown area, which
indicated that bulky lipophilic properties at this site were essential for the potency.
Figure 4 The hydrophobic interactions between the InhA-binding site and compound 6j (A) and compound 9c (B).
Figure 5 (A) All ligands with docked alignment (B) Overlay of 9c (magenta), PT70 (green) and TCL (Blue) in InhA.
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5.1. Molecular docking simulations
Docking as one of the approaches to computer-aided drug de-
sign (CADD) plays an essential role in the design of potential
ligands that are both sterically and chemically compatible with
the binding site of a target bio-macromolecule. (Wermuth,
1996; Cohen, 1996). When performed with default settings,
docking reveals a number of possible conformations and orien-
tations for the inhibitors at the binding site. Understanding the
binding site conformations helps to show the important inter-
actions that stabilize the complex ligand-receptor. The 3D
structures of the pyrrole derivatives were constructed usingstandard geometric parameters of the molecular modeling soft-
ware package Sybyl-X 2.0 (Tripos International, 2012). Each
single optimized conformation of each molecule in the data
set was energetically minimized employing the Tripos force
ﬁeld (Clark et al., 1989) and the Powell conjugate gradient
algorithm (Powell, 1977) with a convergence criterion of
0.05 kcal/mol A˚ and Gasteiger-Hu¨ckel charges (Gasteiger
and Marsili, 1980). Surﬂex-Dock that adopted an empirical
scoring function and a patented searching engine (Jain, 1996,
2003) was employed for molecular docking study. The crystal
structure of M. tuberculosis InhA inhibited by PT70 (PDB en-
try code 2X22) was extracted from the Brookhaven Protein
Database (PDB http://www.rcsb.org/pdb). Co-crystalized li-
gand was removed from the structure, water molecules were
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ing protein preparation. Protein structure minimization was
performed by applying Tripos force ﬁeld and partial atomic
charges were calculated by the Gasteiger-Huckel method. Sur-
ﬂex-Dock scores (total scores) were expressed in kcal/mol units
to represent binding afﬁnities. To identify the ligand–protein
interactions, the top pose and protein were loaded into work
area and the MOLCAD (Molecular Computer Aided Design)
program was employed to visualize the binding mode between
the protein and ligand. MOLCAD calculates and exhibits the
surfaces of channels and cavities, as well as the separating sur-
face between protein subunits (Ai et al., 2010; Lan et al., 2011,
2010). MOLCAD program provides several types to create a
molecular surface. The fast Connolly method using a marching
cube algorithm to engender the surface was applied in this
work, thus the MOLCAD Robbin and Multi-Channel surface
program exhibited with copious potentials were established.
5.2. Chemistry protocols
Chemicals used in the synthesis of compounds were purchased
from Sigma–Aldrich, S. D. Fine-Chem Limited and Spectro-
chem Pvt. Ltd. All the solvents were of reagent grade and when
necessary, they were puriﬁed and dried by the standard meth-
ods. Melting points (M.p.) of the synthesized compounds were
determined on Shital Scientiﬁc Industries (Mumbai, India)
melting point apparatus and are uncorrected; Infrared spectra
were recorded on a Bruker spectrophotometer using KBr pel-
lets. 1H and 13C NMR spectra were recorded on Bruker
AVANCE II 400 MHz instruments using DMSO-d6/CDCl3
as a solvent and TMS as an internal standard; chemical shifts
are expressed as d values (ppm). The J values are expressed in
Hertz (Hz). Mass spectra (MS) were taken in JEOL GCMATE
II GC–Mass spectrometer using electron impact ionization
(EI) technique. Microanalyses of the compounds were per-
formed on Leco Tru Spec CHNS Analyzer to estimate C, H
and N elements. All the new compounds exhibited spectral
data that are consistent with the proposed structures and the
microanalysis data are within ±0.4% of the theoretical values.
Analytical thin-layer chromatography (TLC) was performed
on precoated TLC sheets of silica gel 60 F254 (Merck, Darms-
tadt, Germany), visualized by long- and short-wavelength UV
lamps. Chromatographic puriﬁcations were performed on
Merck aluminum oxide (70–230 mesh) and Merck silica gel
(70–230 mesh).5.2.1. Synthesis of 4-pyrrol-1-yl benzoic acid hydrazide (4)
(Joshi et al., 2008)
Ethyl 4-pyrrol-1-yl benzoate (3) (3.22 g, 15 mmol) was reﬂuxed
with hydrazine hydrate (10 mL) in absolute ethanol (10 mL)
for 3 h. The reaction mixture was cooled and the crystalline
mass obtained was recrystallized from ethanol (yield 74%)
mp 180–182 C.5.2.2. General procedure for the synthesis of 4-pyrrol-1-yl
benzoic acid (arylidene) hydrazides (5a–e)
Equimolar quantity of 4-pyrrol-1-yl-benzoic acid hydrazide
and different aldehydes was reﬂuxed in alcohol for 4–6 h in
the presence of few drops of glacial acetic acid. Solvent was
evaporated and the product was poured onto cold water,ﬁltered and dried. The crude solid was recrystallized in appro-
priate solvent systems to give the products.
5.2.2.1. (E)-N0-(4-Chlorobenzylidene)-4-(1H-pyrrol-1-yl)
benzohydrazide (5a). Compound 5a was obtained as pale yel-
low solid. Yield 82%, M.p. 250–252 C, Rf = 0.37 (Silica gel,
Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3270
(NH), 3048 (C–H aromatic), 1653 (C‚O); 1H NMR (DMSO,
400 MHz) d: 11.91 (s, 1H, NH), 8.47 (s, 1H, N‚CH), 8.05 (d,
2H, phenyl-C3 and C5-H), 7.77 (d, 2H, phenyl-C2 and C6-H),
7.68 (d, 2H, 4-chlorophenyl-C2 and C6-H), 7.46 (d, 2H, 4-chlo-
rophenyl-C3 and C5-H), 7.39 (dd, 2H, pyrrole-C2 and C5-H),
6.32 (dd, 2H, pyrrole-C3 and C4-H);
13C NMR (DMSO,
100 MHz) d: 162.20, 148.22, 143.02, 136.02, 133.79, 129.82,
129.41, 129.15, 118.96, 111.67; MS (EI) m/z: found 323.11
(M+), 325.25 (M+2)+; calcd. 323.08. Anal. Calcd for
C18H14ClN3O; Calc: C, 66.77; H, 4.36; N, 12.98; found: C,
66.50; H, 4.38; N, 13.03.
5.2.2.2. (E)-N0-(3-Bromobenzylidene)-4-(1H-pyrrol-1-yl)
benzohydrazide (5b). Compound 5b was obtained as yellow
solid. Yield 79%, M.p. 191–194 C, Rf = 0.33 (Silica gel,
Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3205
(NH), 3040 (C–H aromatic), 1647 (C‚O); 1H NMR (DMSO,
400 MHz) d: 11.94 (s, 1H, NH), 8.44 (s, 1H, N‚CH), 8.06 (d,
2H, phenyl-C3 and C5-H), 7.35–7.70 (m, 8H, pyrrole-C2 and
C5-H, phenyl-C2 and C6-H, 3-bromophenyl-C2, C3, C4 and
C6-H), 6.32 (dd, 2H, pyrrole-C3 and C4-H);
13C NMR
(DMSO, 100 MHz) d: 163.25, 146.72, 143.72, 136.15, 133.95,
133.80, 129.68, 129.56, 129.22, 128.55, 128.12, 123.15, 120.26,
112.12; MS (EI) m/z: found 367.22 (M+), 369.19 (M++2);
calcd. 367.03. Anal. Calcd for C18H14BrN3O; Calc: C, 58.71;
H, 3.83; N, 11.41; found: C, 58.48; H, 3.85; N, 11.36.
5.2.2.3. (E)-N0-(4-Fluorobenzylidene)-4-(1H-pyrrol-1-yl)ben-
zohydrazide (5c). Compound 5c was obtained as yellow solid.
Yield 71%, M.p. 231–233 C, Rf = 0.34 (Silica gel, Chloro-
form/Methanol 9:1); IR (KBr) mmax: cm
1: 3271 (NH), 3034
(C–H aromatic), 1649 (C‚O); 1H NMR (DMSO, 400 MHz)
d: 11.84 (s, 1H, NH), 8.48 (s, 1H, N‚CH), 7.19–8.05 (m,
10H, pyrrole-C2 and C5-H, Ph-C2, C3, C5 and C6-H, 4-ﬂuoro-
phenyl-C2, C3, C5 and C6-H), 6.31 (dd, 2H, pyrrole-C3 and C4-
H); 13C NMR (DMSO, 100 MHz) d: 166.78, 163.14, 147.12,
143.82, 129.62, 129.51, 129.32, 128.52, 120.96, 118.45, 111.22;
MS (EI) m/z: found 307.03 (M+), 308.12 (M+1)+; calcd.
307.11. Anal. Calcd for C18H14FN3O; Calc: C, 70.35; H,
4.59; N, 13.67; found: C, 70.63; H, 4.57; N, 13.62.
5.2.2.4. (E)-N0-(2,4-Dichlorobenzylidene)-4-(1H-pyrrol-1-yl)
benzohydrazide (5d). Compound 5d was obtained as yellow
solid. Yield 67%, M.p. 229–231 C, Rf = 0.36 (Silica gel,
Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3192
(NH), 3044 (C–H aromatic), 1649 (C‚O); 1H NMR (DMSO,
400 MHz) d: 12.11 (s, 1H, NH), 8.84 (s, 1H, N‚CH), 7.40–
8.18 (m, 9H, pyrrole-C2 and C5-H, Ph-C2, C3, C5 and C6-H,
dichlorophenyl-C3, C5 and C6-H), 6.32 (dd, 2H, pyrrole-C3
and C4-H);
13C NMR (DMSO, 100 MHz) d: 163.28, 143.15,
140.23, 133.53, 128.41, 131.12, 129.80, 129.42, 129.22, 129.02,
128.15, 127.10, 120.43, 110.26; MS (EI) m/z: found 357.36
(M+), 359.14 (M+2)+; calcd. 357.04. Anal. Calcd for
C18H13Cl2N3O; Calc: C, 60.35; H, 3.66; N, 11.73; found: C,
60.59; H, 3.65; N, 11.78.
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yl)benzohydrazide (5e). Compound 5e was obtained as yellow
solid. Yield 69%, M.p. 233–235 C, Rf = 0.35 (Silica gel,
Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3209
(NH), 3049 (C–H aromatic), 1650 (C‚O); 1H NMR (DMSO,
400 MHz) d: 12.14 (s, 1H, NH), 8.92 (s, 1H, N‚CH), 7.61–
8.08 (m, 6H, Ph-C2, C3, C5 and C6-H, dichlorophenyl-C4
and C6-H), 7.42 (m, 3H, pyrrole-C3 and C5-H, dichloro-
phenyl-C5-H), 6.32 (dd, 2H, pyrrole-C3 and C4-H);
13C
NMR (DMSO, 100 MHz) d: 163.48, 146.33, 143.22, 142.26,
135.25, 132.26, 130.78, 129.88, 129.25, 129.19, 128.32, 125.12,
120.23, 111.56; MS (EI) m/z: found 357.21 (M+), 359.32
(M++2); calcd. 357.04. Anal. Calcd for C18H13Cl2N3O; Calc:
C, 60.35; H, 3.66; N, 11.73; found: C, 60.11; H, 3.67; N, 11.77.
5.2.2.6. (E)-N0-(2-Hydroxybenzylidene)-4-(1H-pyrrol-1-
yl)benzohydrazide (5f). Compound 5f was obtained as pale
yellow solid. Yield 83%, M.p. 235–237 C, Rf = 0.21 (Silica
gel, Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3505
(OH), 3217 (NH), 3060 (C–H aromatic), 1647 (C‚O); 1H
NMR (DMSO, 400 MHz) d: 12.01 (s, 1H, NH), 11.57 (s,
1H, OH), 8.58 (s, 1H, N‚CH), 8.08 (d, 2H, phenyl-C3 and
C5-H), 7.57 (d, 2H, phenyl-C2 and C6-H), 6.88–7.34 (m, 6H,
pyrrole-C2 and C5-H, 2-hydroxyphenyl-C3, C4, C5 and C6-
H), 6.34 (dd, 2H, pyrrole-C3 and C4-H);
13C NMR (DMSO,
100 MHz) d: 162.43, 157.95, 148.71, 131.82, 130.01, 129.83,
129.42, 119.50, 119.16, 119.01, 116.89, 111.71; MS (EI) m/z:
found 305.33 (M+); calcd. 305.12. Anal. Calcd for
C18H15N3O2; Calc: C, 70.81; H, 4.95; N, 13.76; found: C,
70.53; H, 4.97; N, 13.70.
5.2.2.7. (E)-N0-(3-Hydroxybenzylidene)-4-(1H-pyrrol-1-
yl)benzohydrazide (5g). Compound 5g was obtained as pale
yellow solid. Yield 65%, M.p. 222–224 C, Rf = 0.41 (Silica
gel, Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3405
(OH), 3281 (NH), 3138 (C–H aromatic), 1637 (C‚O); 1H
NMR (DMSO, 300 MHz) d: 9.65 (s, 1H, NH), 8.40 (s, 1H,
N‚CH), 8.01 (d, 2H, phenyl-C3 and C5-H), 7.70 (d, 2H, phe-
nyl-C2 and C6-H), 7.50 (dd, 2H, pyrrole-C2 and C5-H), 7.30
(m, 3H, 3-hydroxyphenyl-C2, C5 and C6-H), 7.10 (s, 1H, 3-
hydroxyphenyl-C4-H), 6.80 (s, 1H, OH), 6.30 (dd, 2H, pyr-
role-C3 and C4-H);
13C NMR (DMSO, 100 MHz) d: 162.68,
158.16, 148.30, 142.71, 136.10, 130.35, 130.10, 129.79, 119.49,
119.27, 118.96, 113.11, 111.66; MS (EI) m/z: found 305.10
(M+); calcd. 305.12. Anal. Calcd for C18H15N3O2; Calc: C,
70.81; H, 4.95; N, 13.76; found: C, 71.09; H, 4.93; N, 13.71.
5.2.2.8. (E)-N0-(3,4-Dimethoxybenzylidene)-4-(1H-pyrrol-1-
yl)benzohydrazide (5h). Compound 5h was obtained as
brownish yellow solid. Yield 68%, M.p. 203–205 C,
Rf = 0.27 (Silica gel, Chloroform/Methanol 9:1); IR (KBr)
mmax: cm
1: 3244 (NH), 3049 (C–H aromatic), 1648 (C‚O);
1H NMR (DMSO, 400 MHz) d: 11.76 (s, 1H, NH), 8.04 (d,
2H, phenyl-C3 and C5-H), 7.70 (d, 2H, phenyl-C2 and C6-H),
7.42 (m, 3H, pyrrol-C2 and C5-H, dimethoxyphenyl-C5-H),
7.21 (t, 1H, dimethoxyphenyl-C6-H), 7.00 (d, 1H, dimethoxy-
phenyl-C2-H), 6.31 (dd, 2H, pyrrole-C3 and C4-H), 3.84 (s,
6H, 2OCH3);
13C NMR (DMSO, 100 MHz) d: 162.58, 151.25,
149.58, 148.43, 142.64, 130.25, 129.73, 127.56, 119.50, 118.97,
112.04, 111.63, 108.85, 56.06; MS (EI) m/z: found 349.22
(M+); calcd. 349.14. Anal. Calcd for C20H19N3O3; Calc: C,
68.75; H, 5.48; N, 12.03; found: C, 69.03; H, 5.46; N, 11.98.5.2.2.9. (E)-N0-(4-Hydroxy-3-methoxybenzylidene)-4-(1H-
pyrrol-1-yl)benzohydrazide (5i). Compound 5i was obtained
as yellow solid. Yield 72%, M.p. 248–250 C, Rf = 0.45 (Silica
gel, Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3406
(OH), 3226 (NH), 3070 (C–H aromatic), 1636 (C‚O); 1H
NMR (DMSO, 400 MHz) d: 11.66 (s, 1H, NH), 9.40 (s, 1H,
OH), 8.36 (s, 1H, N‚CH), 8.04 (d, 2H, Ph-C2 and C6-H),
7.67 (d, 2H, Ph-C3 and C5-H), 7.06–7.39 (m, 4H, hydroxylphe-
nyl-C2 and C6-H, pyrrole-C2 and C5-H), 6.85 (d, 1H, hydrox-
ylphenyl-C6-H), 6.31 (dd, 2H, pyrrole-C3 and C4-H), 3.87 (s,
3H, OCH3);
13C NMR (DMSO, 100 MHz) d: 162.23, 151.00,
149.27, 146.35, 144.00, 131.02, 129.52, 129.47, 128.11, 122.97,
120.05, 117.35, 112.01, 109.93, 56.09; MS (EI) m/z: found
335.02 (M+); calcd. 335.13. Anal. Calcd for C19H17N3O3;
Calc: C, 68.05; H, 5.11; N, 12.53; found: C, 68.32; H, 5.09;
N, 12.48.
5.2.2.10. (E)-N0-(3-Ethoxy-4-hydroxybenzylidene)-4-(1H-pyr-
rol-1-yl)benzohydrazide (5j). Compound 5j was obtained as
yellow solid. Yield 67%, M.p. 230–234 C, Rf = 0.36 (Silica
gel, Chloroform/Methanol 9:1); IR (KBr) mmax: cm
1: 3367
(OH), 3236 (NH), 3063 (C–H aromatic), 1642 (C‚O); 1H
NMR (DMSO, 400 MHz) d: 11.63 (s,1H, NH), 9.32 (s,1H,
OH), 8.35 (s, 1H, N‚CH), 8.03 (d, 2H, Ph-C3 and C5-H),
7.66 (d, 2H, Ph-C2 and C6-H), 6.84–7.38 (m, 5H, pyrrole-C3
and C5-H, hydroxyl phenyl-C2, C5 and C6-H), 6.31 (dd, 2H,
pyrrole-C3 and C4-H), 4.11 (t, 2H, CH2), 1.43 (t, 3H, CH3);
13C NMR (DMSO, 100 MHz) d: 162.26, 151.27, 148.26,
146.70, 143.72, 130.22, 129.56, 129.44, 128.09, 122.25, 120.01,
116.51, 112.23, 109.97, 64.89, 14.80; MS (EI) m/z: found
349.35 (M+); calcd. 349.14. Anal. Calcd for C20H19N3O3;
Calc: C, 68.75; H, 5.48; N, 12.03; found: C, 69.02; H, 5.47;
N, 12.08.5.2.3. General procedure for the synthesis of 3-acetyl-5-(4-
pyrrol-1-yl phenyl)-2-substituted phenyl-1,3,4-oxadiazolines
(6a–j)
A mixture of 5 (0.003 mol) and acetic anhydride (10 mL) was
heated under reﬂux for 4–6 h. After the reaction mixture was
attained room temperature, excess acetic anhydride was
decomposed by water and the mixture was stirred for further
30 min. The separated product was ﬁltered, washed with water,
dried and recrystallized in appropriate solvent systems to give
the products.
5.2.3.1. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(4-chlorophenyl)-
1,3,4-oxadiazol-3(2H)-yl)ethanone (6a). Compound 6a was
obtained as yellow solid. Yield 75%, M.p. 156–160 C,
Rf = 0.15 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 3253 (NH), 3033 (C–H aromatic), 1652
(C‚O); 1H NMR (DMSO, 400 MHz) d: 8.01 (d, 2H, phe-
nyl-C3 and C5-H), 7.69 (d, 2H, phenyl-C2 and C6-H), 7.55
(d, 2H, 4-chlorophenyl-C2 and C6-H), 7.42 (d, 2H, 4-chloro-
phenyl-C3 and C5-H), 7.38 (dd, 2H, pyrrole-C2 and C5-H),
7.08 (s, 1H, oxadiazole-C2-H), 6.30 (dd, 2H, pyrrole-C3 and
C4-H); 2.30 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz)
d: 164.30, 156.13, 144.71, 139.22, 132.27, 129.81, 129.33,
129.47, 128.63, 128.63, 128.28, 120.42, 109.88, 84.01,
23.31;MS (EI) m/z: found 365.26 (M+); calcd. 365.09. Anal.
Calcd for C20H16ClN3O2; Calc: C, 65.67; H, 4.41; N, 11.49;
found: C, 65.41; H, 4.43; N, 11.44.
52 S.D. Joshi et al.5.2.3.2. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(3-bromophenyl)-
1,3,4-oxadiazol-3(2H)-yl)ethanone (6b). Compound 6b was
obtained as yellow solid. Yield 79%, M.p. 130–132 C,
Rf = 0.13 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 2922 (C–H aromatic), 1668 (C‚O); 1H
NMR (DMSO, 400 MHz) d: 7.40–7.92 (m, 8H, 3-bromophe-
nyl-C2, C4, C5 and C6-H, phenyl-C2, C3, C5 and C6-H), 7.36
(dd, 2H, pyrrole-C2 and C5-H), 7.14 (s, 1H, oxadiazole-C2-
H), 6.31 (dd, 2H, pyrrole-C3 and C4-H), 2.31 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz) d: 165.03, 155.39, 143.27,
139.30, 131.27, 129.74, 129.40, 129.22, 129.09, 122.43, 120.01,
110.73, 83.25, 23.35; MS (EI) m/z: found 409.11 (M+); calcd.
409.04. Anal. Calcd for C20H16BrN3O2; Calc: C, 58.55; H,
3.93; N, 10.24; found: C, 58.78; H, 3.91; N, 10.28.
5.2.3.3. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(4-ﬂuorophenyl)-
1,3,4-oxadiazol-3(2H)-yl)ethanone (6c). Compound 6c was
obtained as brown solid. Yield 68%, M.p. 162–164 C,
Rf = 0.21 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 2955, 2839 (C–H aromatic), 1680 (C‚O);
1H NMR (DMSO, 400 MHz) d: 7.41–8.00 (m, 8H, Ph-C2,
C3, C5 and C6-H, 4-ﬂuorophenyl-C2,C3, C5 and C6-H), 7.38
(dd, 2H, pyrrole-C2 and C5-H), 7.11 (s, 1H, oxadiazole-C2-
H), 6.32 (dd, 2H, pyrrole-C3 and C4-H); 2.30 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz) d: 167.23, 161.00, 156.23,
143.29, 135.23, 129.83, 129.43, 129.11, 128.35, 120.09, 115.23,
109.88, 83.43, 23.30; MS (EI) m/z: found 349.05 (M+); calcd.
349.12. Anal. Calcd for C20H16FN3O2; Calc: C, 68.76; H,
4.62; N, 12.03; found: C, 68.48; H, 4.64; N, 12.08.
5.2.3.4. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(2,4-dichloro-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6d). Compound
6d was obtained as yellow solid. Yield 66%, M.p. 149–
151 C, Rf = 0.20 (Silica gel, Ethyl acetate/petroleum ether
6:4); IR (KBr) mmax: cm
1: 2951, 2840 (C–H aromatic), 1675
(C‚O), 715 (C–Cl); 1H NMR (CDCl3, 400 MHz) d: 7.55–
8.15 (m, 7H, Ph-C2, C3, C5 and C6-H, dichlorophenyl-C3, C5
and C6-H), 7.36 (dd, 2H, pyrrole-C2 and C5-H), 7.14 (s, 1H,
oxadiazole-C2-H), 6.33 (dd, 2H, pyrrole-C3 and C4-H); 2.31
(s, 3H, COCH3);
13C NMR (CDCl3, 100 MHz) d: 167.20,
157.00, 143.09, 140.53, 133.63, 130.23, 129.77, 129.63, 129.44,
129.29, 126.71, 119.80, 110.60, 78.39, 23.35; MS (EI) m/z:
found 399.39 (M+), 401.33 (M++2); calcd. 399.05. Anal.
Calcd for C20H15Cl2N3O2; Calc: C, 60.01; H, 3.78; N, 10.50;
found: C, 59.77; H, 3.80; N, 10.46.
5.2.3.5. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(2,3-dichloro-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6e). Compound
6e was obtained as yellow solid. Yield 63%, M.p. 147–149 C,
Rf = 0.19 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 2945, 2840 (C–H aromatic), 1677 (C‚O),
717 (C–Cl); 1H NMR (CDCl3, 400 MHz) d: 8.03 (d, 2H, phe-
nyl-C3 and C5-H), 7.81–7.69 (m, 3H, Ph-C2, C6-H and dichloro-
phenyl-C4-H) 7.61–8.08 (m, 6H, and C6-H, and C6-H), 7.50–
7.38 (m, 4H, pyrrole-C3 and C5-H, dichlorophenyl-C5, C6-H),
7.11 (s, 1H, oxadiazole-C2-H), 6.30 (dd, 2H, pyrrole-C3 and
C4-H); 2.20 (s, 3H, COCH3);
13C NMR (CDCl3, 100 MHz) d:
165.34, 155.29, 145.01, 143.29, 133.45, 129.63, 129.42, 129.27,
128.19, 128.03, 127.63, 126.31, 120.19, 110.19, 77.39, 23.39;
MS (EI) m/z: found 399.12 (M+), 401.21 (M++2); calcd.
399.05. Anal. Calcd for C20H15Cl2N3O2; Calc: C, 60.01; H,
3.78; N, 10.50; found: C, 60.25; H, 3.76; N, 10.47.5.2.3.6. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(2-hydroxy-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6f). Compound
6f was obtained as yellow solid. Yield 73%, M.p. 147–149 C,
Rf = 0.19 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 3450 (OH), 2919 (C–H aromatic), 1662
(C‚O); 1H NMR (DMSO, 400 MHz) d: 8.09 (s, 1H, OH), 7.88
(d, 2H, phenyl-C3 and C5-H), 7.29–7.53 (m, 5H, 2-hydroxy-
phenyl-C3, C4, C5 and C6-H), 7.65 (d, 2H, phenyl-C2 and C6-H),
7.33 (s, 2H, pyrrole-C2 and C5-H), 7.11 (s, 1H, oxadiazole-C2-
H), 6.30 (s, 2H, pyrrole-C3 and C4-H), 2.18 (s, 3H, COCH3);
13C
NMR (DMSO, 100 MHz) d: 165.01, 155.02, 153.27, 129.80,
129.53, 129.44, 129.29, 128.29, 128.09, 121.10, 120.11, 115.65,
110.11, 77.24, 23.39; MS (EI) m/z: found 347.29 (M+); calcd.
347.13. Anal. Calcd for C20H17N3O3; Calc: C, 69.15; H, 4.93; N,
12.10; found: C, 69.43; H, 4.91; N, 12.15.
5.2.3.7. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(3-hydroxy-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6g). Compound
6g was obtained as yellow solid. Yield 73%, M.p. 147–149 C,
Rf = 0.19 (Silica gel, Ethyl acetate/petroleum ether 6:4); IR
(KBr) mmax: cm
1: 3452 (OH), 2922 (C–H aromatic), 1667
(C‚O); 1H NMR (DMSO, 400 MHz) d: 7.99 (d, 2H, phenyl-C3
and C5-H), 7.65 (d, 2H, phenyl-C2 and C6-H), 7.33 (d, 2H, pyr-
role-C2 and C5-H), 7.26 (m, 3H, 3-hydroxyphenyl-C2, C5 and
C6-H), 7.05 (s, 1H, oxadiazole-C2-H), 7.09 (s, 1H, 3-hydroxy-
phenyl-C4-H), 6.93 (s, 1H, OH), 6.31 (dd, 2H, pyrrole-C3 and
C4-H), 2.26 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz) d:
165.29, 156.21, 155.33, 144.29, 141.69, 130.11, 129.79, 129.43,
129.09, 120.03, 119.45, 113.88, 112.53, 110.05, 83.79, 23.31; MS
(EI) m/z: found 347.55 (M+), 349.01 (M++2); calcd. 347.13.
Anal. Calcd for C20H17N3O3; Calc: C, 69.15; H, 4.93; N,
12.10; found: C, 68.87; H, 4.95; N, 12.14.
5.2.3.8. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(3,4-dimethoxy-
phenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6h). Compound
6h was obtained as yellow solid. Yield 68%, M.p. 146–
148 C, Rf = 0.17 (Silica gel, Ethyl acetate/petroleum ether
6:4); IR (KBr) mmax: cm
1: 2924 (C–H aromatic), 1666
(C‚O); 1H NMR (DMSO, 400 MHz) d: 7.91 (d, 2H, phe-
nyl-C3 and C5-H), 7.66 (d, 2H, phenyl-C2 and C6-H), 7.35
(dd, 2H, pyrrole-C2 and C5-H), 7.07 (s, 1H, oxadiazole-C2-
H), 6.93–7.03 (m, 3H, dimethoxyphenyl-C2, C5 and C6-H),
6.31 (dd, 2H, pyrrole-C3 and C4-H), 2.30 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz) d: 167.22, 156.21, 150.00,
148.03, 142.61, 133.40, 129.75, 129.50, 129.27, 120.11, 119.77,
112.00, 112.19, 110.67, 83.49, 56.06, 23.37; MS (EI) m/z: found
391.41 (M+); calcd. 391.15. Anal. Calcd for C22H21N3O4;
Calc: C, 67.51; H, 5.41; N, 10.74; found: C, 67.24; H, 5.43;
N, 10.70.
5.2.3.9. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(4-hydroxy-3-
methoxyphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6i).
Compound 6i was obtained as yellow solid. Yield 69%, M.p.
155–158 C, Rf = 0.15 (Silica gel, Ethyl acetate/petroleum
ether 6:4); IR (KBr) mmax: cm
1: 3440 (OH), 2927 (C–H aro-
matic), 1670 (C‚O); 1H NMR (DMSO, 400 MHz) d: 8.77
(s, 1H, OH), 8.03 (d, 2H, Ph-C2 and C6-H), 7.70 (d, 2H, Ph-
C3 and C5-H), 7.40–6.89 (m, 5H, hydroxylphenyl-C2 and C6-
H, pyrrole-C2 and C5-H, oxadiazole-C2-H), 6.80 (d, 1H,
hydroxylphenyl-C6-H), 6.30 (dd, 2H, pyrrole-C3 and C4-H),
3.85 (s, 3H, OCH3), 2.31 (s, 3H, COCH3);
13C NMR (DMSO,
100 MHz) d: 165.29, 157.36, 147.50, 146.43, 142.59, 135.01,
Synthesis and molecular modeling studies of novel pyrrole analogs as antimycobacterial agents 53129.63, 129.30, 129.17, 120.60, 120.07, 115.33, 112.45, 109.99,
83.70, 56.08, 23.33; MS (EI) m/z: found 377.27 (M+); calcd.
377.14. Anal. Calcd for C21H19N3O4; Calc: C, 66.83; H,
5.07; N, 11.13; found: C, 67.10; H, 5.05; N, 11.09.
5.2.3.10. 1-(5-(4-(1H-Pyrrol-1-yl)phenyl)-2-(3-ethoxy-4-
hydroxyphenyl)-1,3,4-oxadiazol-3(2H)-yl)ethanone (6j).
Compound 6j was obtained as yellow solid. Yield 67%, M.p.
157–159 C, Rf = 0.17 (Silica gel, Ethyl acetate/petroleum
ether 6:4); IR (KBr) mmax: cm
1: 3441 (OH), 2950, 2831 (C–
H aromatic), 1669 (C‚O); 1H NMR (DMSO, 400 MHz) d:
8.11 (s,1H, OH), 7.89 (d, 2H, Ph-C3 and C5-H), 7.70 (d, 2H,
Ph-C2 and C6-H), 7.35–6.90 (m, 6H, pyrrole-C2 and C5-H,
hydroxylphenyl-C2, C5 and C6-H, oxadiazole-C2-H), 6.30 (s,
2H, pyrrole-C3 and C4-H), 4.09 (t, 2H, CH2), 1.40 (t, 3H,
CH3), 2.29 (s, 3H, COCH3);
13C NMR (DMSO, 100 MHz)
d: 165.31, 157.00, 148.03, 146.65, 143.00, 133.39, 129.73,
129.40, 129.28, 120.11, 119.93, 115.00, 112.38, 110.79, 83.74,
64.57, 23.30, 14.77; MS (EI) m/z: found 391.31 (M+); calcd.
391.15. Anal. Calcd for C22H21N3O4; Calc: C, 67.51; H,
5.41; N, 10.74; found: C, 67.78; H, 5.39; N, 10.78.
5.2.4. Synthesis of phthalazine and pyridazine derivatives 7a–h
A mixture of 4-pyrrol-1-yl-benzoic acid hydrazide (0.01 mol)
and appropriate aromatic anhydrides (0.01 mol) in 5 mL abso-
lute ethanol and glacial acetic acid (0.005 mol) was reﬂuxed for
4–6 h. The reaction mixture was poured into crushed ice. The
solid obtained was ﬁltered, washed with dilute sodium bicar-
bonate solution and recrystallized with suitable solvent.
5.2.4.1. 1-(4-(1H-Pyrrol-1-yl)benzoyl)piperazine-3,6-dione
(7a). Compound 7a was obtained as yellow solid. Yield
83%, M.p. 261–263 C, Rf = 0.32 (Silica gel, Chloroform/
methanol 9:1); IR (KBr) mmax: cm
1: 3355 (N–H), 2920 (C–H
aromatic), 1729 (C‚O); 1H NMR (DMSO-d6, 400 MHz) d:
11.02 (s, 1H, NH), 8.05 (dd, 2H, phenyl-C3 and C5-H), 7.69
(dd, 2H, phenyl-C2 and C6-H), 7.40 (dd, 2H, pyrrole-C2 and
C5-H), 6.32 (dd, 2H, pyrrole-C3 and C4-H), 2.86 (s, 4H, piper-
azine-2CH2);
13C NMR (DMSO-d6, 100 MHz) d: 174.85,
174.41, 172.42, 143.85, 131.0, 129.54, 128.19, 120.00, 110.15,
28.25, 25.51; MS (EI) m/z: found 283.56 (M+); calcd.
283.10. Anal. Calcd for C15H13N3O3; Calc: C, 63.60; H,
4.63; N, 14.83; found: C, 63.35; H, 4.65; N, 14.89.
5.2.4.2. 1-(4-(1H-Pyrrol-1-yl)benzoyl)-1,2-dihydropyridazine-
3,6-dione (7b). Compound 7b was obtained as yellow solid.
Yield 79%, M.p. 225–227 C, Rf = 0.39 (Silica gel, Chloro-
form/methanol 9:1); IR (KBr) mmax: cm
1: 3262 (N–H), 2923
(C–H aromatic), 1735 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 11.02 (s, 1H, NH), 8.05 (dd, 2H, phenyl-C3 and
C5-H), 7.69 (dd, 2H, phenyl-C2 and C6-H), 7.40 (dd, 2H, pyr-
role-C2 and C5-H), 6.95 (s, 2H, piperazine-2CH), 6.32 (dd, 2H,
pyrrole-C3 and C4-H);
13C NMR (CDCl3, 100 MHz) d: 172.49,
157.24, 156.25, 142.91, 130.59, 129.00, 128.67, 128.04, 121.01,
110.85; MS (EI) m/z: found 281.33 (M+); calcd. 281.08. Anal.
Calcd for C15H11N3O3; Calc: C, 64.05; H, 3.94; N, 14.94;
found: C, 63.79; H, 3.96; N, 14.88.
5.2.4.3. 2-(4-(1H-Pyrrol-1-yl)benzoyl)-2,3-dihydrophthalazine-
1,4-dione (7c). Compound 7c was obtained as yellow solid.
Yield 68%, M.p. 233–236 C, Rf = 0.41 (Silica gel, Chloro-
form/methanol 9:1); IR (KBr) mmax: cm
1: 3377 (N–H), 2923(C–H aromatic), 1792 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 11.30 (s, 1H, NH), 7.67–8.08 (m, 8H, phenyl-
C2, C3, C5, C6-H, pthalazine-C6, C7, C8, and C9-H), 7.48
(dd, 2H, pyrrole-C2 and C5-H), 6.32 (dd, 2H, pyrrole-C3 and
C4-H);
13C NMR (DMSO, 100 MHz) d: 171.90, 168.05,
158.44, 142.98, 132.52, 131.21, 129.04, 128.35, 128.01, 123.03,
120.44, 110.41; MS (EI) m/z: found 331.41 (M+); calcd.
331.10. Anal. Calcd for C19H13N3O3; Calc: C, 68.88; H,
3.95; N, 12.68; found: C, 69.16; H, 3.93; N, 12.63.
5.2.4.4. 1-(4-(1H-Pyrrol-1-yl)benzoyl)-5-methyl-1,2-dihydro-
pyridazine-3,6-dione (7d). Compound 7d was obtained as
yellow solid. Yield 65%, M.p. 220–222 C, Rf = 0.39 (Silica
gel, Chloroform/methanol 9:1); IR (KBr) mmax: cm
1: 3376
(N–H), 2926 (C–H aromatic), 1794 (C‚O); 1H NMR
(DMSO-d6, 400 MHz) d: 11.00 (s, 1H, NH), 8.03 (dd, 2H,
phenyl-C3 and C5-H), 7.78 (dd, 2H, phenyl-C2 and C6-H),
7.40 (dd, 2H, pyrrole-C2 and C5-H), 6.65 (s, H, piperazine-
C5-H), 6.40 (dd, 2H, pyrrole-C3 and C4-H), 2.40 (s, 3H,
piperazine-C4-CH3);
13C NMR (CDCl3, 100 MHz) d: 173.05,
158.08, 156.31, 144.20, 143.05, 140.24, 131.26, 129.28,
128.84, 128.47, 120.59, 110.81, 18.15; MS (EI) m/z: found
295.01 (M+); calcd. 295.10. Anal. Calcd for C16H13N3O3;
Calc: C, 65.08; H, 4.44; N, 14.23; found: C, 65.34; H, 4.42;
N, 14.17.
5.2.4.5. 1-(4-(1H-Pyrrol-1-yl)benzoyl)-5-methylenepiperazine-
3,6-dione (7e). Compound 7e was obtained as yellow solid.
Yield 65%, M.p. 248–250 C, Rf = 0.40 (Silica gel, Chloro-
form/methanol 9:1); IR (KBr) mmax: cm
1: 3272 (N–H), 2918
(C–H aromatic), 1735 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 10.97 (s, 1H, NH), 7.62–8.14 (m, 4H, Ph-C2,
C3, C5, and C6-H), 7.39 (dd, 2H, pyrrole C2 and C5-H), 6.74
(s, 1H, ‚CH2), 6.32 (dd, 2H, pyrrole-C3 and C4-H), 5.84 (s,
1H,‚CH2), 2.13 (s, 2H, piperazine-C4-H);
13C NMR (CDCl3,
100 MHz) d:173.05, 168.11, 157.90, 143.25, 140.87, 131.01,
128.56, 128.94, 124.85, 120.50, 109.88, 32.96; MS (EI) m/z:
found 295.13 (M+); calcd. 295.10. Anal. Calcd for
C16H13N3O3; Calc: C, 65.08; H, 4.44; N, 14.23; found: C,
65.33; H, 4.43; N, 14.19.
5.2.4.6. 2-(4-(1H-Pyrrol-1-yl)benzoyl)-2,3,4a,5,8,8a-hexahy-
dro-5,8-methanophthalazine-1,4-dione (7f). Compound 7f was
obtained as yellow solid. Yield 67%, M.p. 256–258 C,
Rf = 0.48 (Silica gel, Chloroform/methanol 9:1); IR (KBr)
mmax: cm
1: 3269 (N–H), 2921 (C–H aromatic), 1738 (C‚O);
1H NMR (DMSO-d6, 400 MHz) d: 11.07 (s, 1H, NH), 7.59–
8.04 (m, 4H, phenyl-C2, C3, C5, and C6-H), 7.46 (dd, 2H, pyr-
role C2 and C5-H), 6.42 (dd, 2H, pyrrole-C3 and C4-H), 6.34
(d, 2H, methanophthalazine-C10 and C11-H), 3.37 (m, 2H,
methanophthalazine-C5 and C7-H), 2.72 (s, 2H, methanoph-
thalazine-C4 and C8-H), 1.58 (t, 2H, methanophthalazine-C6-
H); 13C NMR (CDCl3, 100 MHz) d: 175.05, 175.60, 173.08,
142.95, 135.84, 131.04, 129.26, 128.61, 120.42, 110.55, 53.08,
49.20, 46.54, 46.06; MS (EI) m/z: found 347.02 (M+); calcd.
347.13. Anal. Calcd for C20H17N3O3; Calc: C, 69.15; H,
4.93; N, 12.10; found: C, 69.43; H, 4.91; N, 12.15.
5.2.4.7. 2-(4-(1H-Pyrrol-1-yl)benzoyl)-2,3,5,6,7,8-hexahydr-
ophthalazine-1,4-dione (7g). Compound 7g was obtained as
yellow solid. Yield 62%, M.p. 241–243 C, Rf = 0.33 (Silica
gel, Chloroform/methanol 9:1); IR (KBr) mmax: cm
1: 3367
54 S.D. Joshi et al.(N–H), 2933 (C–H aromatic), 1789 (C‚O); 1H NMR
(DMSO-d6, 400 MHz) d: 10.98 (s, 1H, NH), 8.05 (dd, 2H, phe-
nyl-C3 and C5-H), 7.69 (dd, 2H, phenyl-C2 and C6-H), 2.30–
1.87 (m, 8H, hexahydrophthalazine-C6, C7, C8 and C9-H),
7.48 (dd, 2H, pyrrole-C2 and C5-H), 6.32 (dd, 2H, pyrrole-C3
and C4-H);
13C NMR (CDCl3, 100 MHz) d:172.45, 158.00,
155.44, 146.02, 143.06, 131.27, 129.51, 128.25, 120.90, 110.28,
28.02, 22.05; MS (EI) m/z: found 335.06 (M+); calcd. 335.13.
Anal. Calcd for C19H17N3O3; Calc: C, 68.05; H, 5.11; N,
12.53; found: C, 67.78; H, 5.13; N, 12.58.
5.2.4.8. 2-(4-(1H-Pyrrol-1-yl)benzoyl)octahydrophthalazine-
1,4-dione (7h). Compound 7h was obtained as yellow solid.
Yield 60%, M.p. 230–232 C, Rf = 0.37 (Silica gel, Chloro-
form/methanol 9:1); IR (KBr) mmax: cm
1: 3367 (N–H), 2933
(C–H aromatic), 1789 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 10.98 (s, 1H, NH), 8.03 (d, 2H, phenyl-C3 and C5-
H), 7.66 (d, 2H, phenyl-C2 and C6-H), 7.48 (dd, 2H, pyrrole-C2
and C5-H), 6.30 (s, 2H, pyrrole-C3 and C4-H); 2.66 (s, 4H, octa-
hydrophthalazine-C4 andC5-H), 1.86–1.49 (m, 8H,octahydroph-
thalazine-C6, C7, C8 and C9-H);
13C NMR (CDCl3, 100 MHz) d:
175.81, 175.00, 172.56, 142.90, 131.25, 129.25, 128.51, 120.08,
110.53, 32.04, 29.21, 27.00, 25.85; MS (EI) m/z: found 337.19
(M+); calcd. 337.14. Anal. Calcd for C19H19N3O3; Calc: C,
67.64; H, 5.68; N, 12.46; found: C, 67.37; H, 5.70; N, 12.41.
5.2.5. Synthesis of phthalazine and pyridazine derivatives 9a–h
A mixture of 4-(2,5-dimethylpyrrol-1-yl) benzoic acid hydra-
zide (0.01 mol) and appropriate aromatic anhydrides
(0.01 mol) in 5 mL absolute ethanol and glacial acetic acid
(0.005 mol) was reﬂuxed for 4–6 h. The reaction mixture was
poured into crushed ice. The solid obtained was ﬁltered,
washed with dilute sodium bicarbonate solution and recrystal-
lized with suitable solvent.
5.2.5.1. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)piperazine-
3,6-dione (9a). Compound 9a was obtained as yellow solid.
Yield 83%, M.p. 265–268 C, Rf = 0.35 (Silica gel, Chloro-
form/methanol 9:1); IR (KBr) mmax: cm
1: 3332 (NH), 2924
(C–H aromatic), 1730 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 11.14 (s, 1H, NH), 8.09 (dd, 2H, phenyl-C3 and
C5-H), 7.40 (d, 2H, phenyl-C2 and C6-H), 5.82 (d, 2H, pyr-
role-C3 and C4-H), 2.87 (s, 4H, piperazine-2CH2), 2.02 (s,
6H, 2CH3);
13C NMR (CDCl3, 100 MHz) d: 174.16, 172.51,
172.05, 142.08, 131.17, 129.09, 128.65, 105.51, 28.15, 25.06,
12.91; MS (EI) m/z: found 311.17 (M+); calcd. 311.13. Anal.
Calcd for C17H17N3O3; Calc: C, 65.58; H, 5.50; N, 13.50;
found: C, 65.84; H, 5.48; N, 13.55.
5.2.5.2. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-1,2-dihyd-
ropyridazine-3,6-dione (9b). Compound 9b was obtained as
yellow solid. Yield 79%, M.p.>300 C, Rf = 0.32 (Silica gel,
Chloroform/methanol 9:1); IR (KBr) mmax: cm
1: 3256 (N–
H), 2974 (C–H aromatic), 1738 (C‚O); 1H NMR (DMSO-
d6, 400 MHz) d: 11.40 (s, 1H, NH), 8.00–8.19 (m, 4H, Ph-C2,
C3, C5 and C6-H), 7.66 (s, 2H, pyridazine-C4 and C5-H),
5.83 (dd, pyrrole-C3 and C4-H), 2.00 (s, 6H, 2CH3);
13C
NMR (CDCl3, 100 MHz) d:172.02, 157.24, 156.00, 142.31,
131.82, 131.20, 130.00, 129.28, 128.82, 105.91, 12.00; MS
(EI) m/z: found 309.07 (M+); calcd. 309.11. Anal. Calcd for
C17H15N3O3; Calc: C, 66.01; H, 4.89; N, 13.58; found: C,
65.75; H, 4.91; N, 13.63.5.2.5.3. 2-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-2,3-
dihydrophthalazine-1,4-dione (9c). Compound 9c was obtained
as yellow solid. Yield 68%,M.p. 230–234 C,Rf = 0.40 (Silica gel,
Chloroform/methanol 9:1); IR (KBr) mmax: cm
1: 3280 (N–H),
2920 (C–H aromatic), 1733 (C‚O); 1H NMR (DMSO-d6,
400 MHz) d: 11.34 (s, 1H, NH), 7.34–8.16 (m, 8H, phenyl-C2, C3,
C5 and C6-H, phthalazine-C5, C6, C7 and C8-H), 5.84 (dd, pyr-
role-C3 and C4-H), 2.04 (s, 6H, 2CH3);
13C NMR (CDCl3,
100 MHz) d:172.11, 167.15, 159.07, 142.03, 132.51, 131.05,
129.27,128.95, 128.56, 128.04, 123.45, 105.05, 12.18; MS (EI) m/z:
found 359.26 (M+); calcd. 359.13. Anal. Calcd for C21H17N3O3;
Calc: C, 70.18;H, 4.77;N, 11.69; found:C, 69.90;H, 4.79;N, 11.64.
5.2.5.4. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-5-methyl-
1,2-dihydropyridazine-3,6-dione (9d). Compound 9d was ob-
tained as yellow solid. Yield 68%, M.p. 266–268 C,
Rf = 0.41 (Silica gel, Chloroform/methanol 9:1); IR (KBr)
mmax: cm
1: 3373 (N–H), 2931 (C–H aromatic), 1787 (C‚O);
1H NMR (DMSO-d6, 400 MHz) d: 11.00 (s, 1H, NH), 8.03
(d, 2H, phenyl-C3 and C5-H), 7.78 (d, 2H, phenyl-C2 and
C6-H), 6.65 (s, H, dihydropyridazine-C5-H), 5.87 (s, 2H, pyr-
role-C3 and C4-H), 2.40 (s, 3H, dihydropyridazine-C5-CH3),
2.06 (s, 6H, 2CH3),.
13C NMR (CDCl3, 100 MHz) d: 172.05,
158.44, 156.21, 144.26, 142.02, 140.28, 131.27, 129.22, 128.80,
128.21, 105.73, 19.01, 12.80; MS (EI) m/z: found 323.11
(M+); calcd. 323.13. Anal. Calcd for C18H17N3O3; Calc: C,
66.86; H, 5.30; N, 13.00; found: C, 67.13; H, 5.28; N, 12.95.
5.2.5.5. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-5-methyl-
enepiperazine-3,6-dione (9e). Compound 9e was obtained as
yellow solid. Yield 65%, M.p. >300 C, Rf = 0.38 (Silica gel,
Chloroform/methanol 9:1); 1H NMR (DMSO-d6, 400 MHz) d:
11.26 (s, 1H, NH), 7.35–8.14 (m, 4H, phenyl-C2, C3, C5 and C6-
H), 6.70 (s, 1H, ‚CH2), 5.83 (s, 3H, pyrrole-C3 and C4-H and
‚CH2), 2.09 (s, 2H, piperazine-C4-H), 2.02 (s, 6H, 2CH3);
13C
NMR (CDCl3, 100 MHz) d:172.52, 168.21, 158.45, 142.24,
140.26,131.04, 129.25, 128.87, 128.22, 124.05, 104.90, 33.24, 12.02;
MS (EI) m/z: found 323.19 (M+); calcd. 323.13. Anal. Calcd for
C18H17N3O3; Calc: C, 66.86; H, 5.30; N, 13.00; found: C, 67.09;
H, 5.31; N, 13.05.
5.2.5.6. 2-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-2,3,4a,5,
8,8a-hexahydro-5,8-methanophthalazine-1,4-dione (9f). Com-
pound 9f was obtained as yellow solid. Yield 62%, M.p.
262–264 C, Rf = 0.40 (Silica gel, Chloroform/methanol 9:1);
IR (KBr) mmax: cm
1: 3269 (N–H), 2921 (C–H aromatic),
1738 (C‚O); 1H NMR (DMSO-d6, 400 MHz) d: 11.07 (s,
1H, NH), 7.59–8.04 (m, 4H, Ph-C2, C3, C5 and C6-H), 6.34
(d, 2H, methanophthalazine-C10 and C11-H), 6.02 (s, 2H, pyr-
role C3 and C4-H), 3.37 (m, 2H, methanophthalazine-C5 and
C7-H), 2.72 (s, 2H, methanophthalazine-C4 and C8-H), 1.83
(s, 6H, 2CH3), 1.58 (t, 2H, methanophthalazine-C6-H);
13C
NMR (CDCl3, 100 MHz) d:175.14, 172.05, 142.08, 135.02,
131.01, 129.06, 128.97, 128.05, 105.01, 53.18, 49.0, 46.77,
46.08, 12.02; MS (EI) m/z: found 375.02 (M+); calcd. 375.16.
Anal. Calcd for C22H21N3O3; Calc: C, 70.38; H, 5.64; N,
11.19; found: C, 70.10; H, 5.66; N, 11.23.
5.2.5.7. 2-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)-2,3,5,6,7,
8-hexahydrophthalazine-1,4-dione (9g). Compound 9g was ob-
tained as yellow solid. Yield 60%, M.p. 277–279 C, Rf = 0.42
(Silica gel, Chloroform/methanol 9:1); IR (KBr) mmax: cm
1:
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(DMSO-d6, 400 MHz) d: 10.98 (s, 1H, NH), 8.05 (dd, 2H, phe-
nyl-C3 and C5-H), 7.69 (dd, 2H, phenyl-C2 and C6-H), 5.88 (s,
2H, pyrrole-C3 and C4-H), 2.31 (s, 4H, hexahydrophthalazine-
C6 and C9-H), 2.00 (s, 6H, 2CH3); 1.85 (s, 4H, hexahydroph-
thalazine-C7 and C8-H);
13C NMR (CDCl3, 100 MHz)
d:172.55, 158.04, 155.22, 145.25, 142.37, 131.02, 129.34,
128.78, 128.27, 105.92, 28.24, 22.45, 12.54; MS (EI) m/z: found
363.11 (M+); calcd. 363.16. Anal. Calcd for C21H21N3O3;
Calc: C, 69.41; H, 5.82; N, 11.56; found: C, 69.13; H, 5.84;
N, 11.51.
5.2.5.8. 2-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoyl)octahydr-
ophthalazine-1,4-dione (9h). Compound 9h was obtained as
yellow solid. Yield 61%, M.p. 281–283 C, Rf = 0.40 (Silica
gel, Chloroform/methanol 9:1); IR (KBr) mmax: cm
1: 3367
(NH), 2933 (C–H aromatic), 1789 (C‚O); 1H NMR
(DMSO-d6, 400 MHz) d: 10.98 (s, 1H, NH), 8.13 (d, 2H, phe-
nyl-C3 and C5-H), 7.60 (d, 2H, phenyl-C2 and C6-H), 5.87 (s,
2H, pyrrole-C3 and C4-H); 2.66 (s, 4H, octahydrophthal-
azine-C4 and C5-H), 1.98 (s, 6H, 2CH3), 1.87–1.50 (m, 8H,
octahydrophthalazine-C6, C7, C8 and C9-H);
13C NMR
(CDCl3, 100 MHz) d:175.80, 175.22, 172.26, 142.45, 131.22,
129.24, 128.90, 128.23, 105.25, 32.01. 29.24, 27.01, 25.15,
12.02; MS (EI) m/z: found 365.02 (M+); calcd. 365.17. Anal.
Calcd for C21H23N3O3; Calc: C, 69.02; H, 6.34; N, 11.50;
found: C, 69.30; H, 6.31; N, 11.45.
5.3. Biological assay
5.3.1. In vitro evaluation of antibacterial activity
The MIC determination of the tested compounds was investi-
gated by a side-by-side comparison with norﬂoxacin against
Gram-positive (S. aureus, B. subtilis) and Gram-negative bac-
teria (V. cholera, E. coli) by the broth microdilution method
(Goto et al., 1981; Villanova, 1985). Serial dilutions of the test
compounds and reference drugs were prepared in Mueller–
Hinton agar. Drugs (10 mg) were dissolved in dimethylsulfox-
ide (DMSO, 1 mL). Further progressive dilutions with melted
Mueller–Hinton agar were performed to obtain the required
concentrations of 0.2, 0.4, 0.8, 1.6, 3.125, 6.25, 12.5, 25, 50
and 100 lg/mL. The tubes were inoculated with 105 cfu mL1
(colony forming unit/mL) and incubated at 37 C for 18 h. The
MIC was the lowest concentration of the tested compound
that yielded no visible growth on the plate. To ensure that
the solvent had no effect on the bacterial growth, a control
was performed with the test medium supplemented with
DMSO at the same dilutions as used in the experiments and
DMSO had no effect on the microorganisms in the concentra-
tions studied. Table 1 reveals the antibacterial activity (MIC
values) of the synthesized compounds.
The MIC values were determined against M. tuberculosis
strain H37Rv using the Micro plate Alamar Blue assay
(MABA) (Franzblau et al., 1998). Isoniazid, rifampicin and
ethambutol were used as standard drugs. The 96 well plate
received 100 lL of the Middlebrook 7H9 broth and serial
dilution of compounds was made directly onto the plate.
The ﬁnal drug concentrations tested were 0.2, 0.4, 0.8, 1.6,
3.125, 6.25, 12.5, 25, 50 and 100 lg/mL. Plates were covered
and sealed with paraﬁlm and incubated at 37 C for ﬁve days.
After this, 25 lL of freshly prepared 1:1 mixture of almarblue reagent and 10% Tween 80 was added to the plate
and incubated for 24 h. A blue color in the well was inter-
preted as no bacterial growth and pink color was scored as
growth. The MIC was deﬁned as the lowest drug concentra-
tion, which prevented the color change from blue to pink.
Table 2 reveals the antitubercular activity (MIC) of the syn-
thesized compounds.
5.3.2. MTT cytotoxicity assay
The cellular conversion of MTT [3-(4,5-dimethylthiazo-2-yl)-
2,5-diphenyl-tetrazolium bromide] into a formazan product
(Mosmann, 1983) was used to evaluate the cytotoxic activity
(IC50) of some synthesized compounds (5a, 5c, 6b, 6c, 6f, 6h,
6j, 7b, 7c, 8b, 8c, 8f, 8g and 8h) against mammalian Vero cell
lines and A549 (lung adenocarcinoma) cell lines up to concen-
trations of 62.5 lg/mL using the Promega Cell Titer 96 non-
radioactive cell proliferation assay (Gundersen et al., 2002).
Cisplatin was used as a positive control. The IC50 values are
means + SEM of three independent experiments and are pre-
sented in Table 2.
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